Global Viral Vector Production Market Size, Share & Trends Analysis Report By Type (Adeno-Associated Viral Vectors, Lentiviral Vectors, Adenoviral Vectors, Retroviral Vectors, and Others), By Indication, By Application, By Regional Outlook and Forecast, 2

Global Viral Vector Production Market Size, Share & Trends Analysis Report By Type (Adeno-Associated Viral Vectors, Lentiviral Vectors, Adenoviral Vectors, Retroviral Vectors, and Others), By Indication, By Application, By Regional Outlook and Forecast, 2023 - 2030


The Global Viral Vector Production Market size is expected to reach $3.9 billion by 2030, rising at a market growth of 19.1% CAGR during the forecast period.

This has created a higher demand for viral vectors in producing these therapies. Regulatory agencies recognizing the potential of gene therapies and offering support, expedited review processes, and incentives have contributed to the growth of the gene therapy. Consequently, the Gene Therapy segment would generate approximately 65.6 share of the market by 2030. This positive regulatory environment has encouraged the development and production of viral vectors. Thus, the rise in demand and awareness for gene therapy has positively impacted the market by creating a growing and dynamic landscape.

Engineering viral vectors for reduced immunogenicity, improved targeting, and controlled gene expression contributes to developing vectors tailored for specific therapeutic applications. Developing next-generation viral vector platforms, such as synthetic and hybrid vectors, expands the toolbox for gene delivery. These platforms aim to overcome limitations associated with traditional vectors, offering improved safety profiles and increased efficiency in gene transfer. Therefore, these advancements collectively drive the expansion of the market. Moreover, A growing pipeline in gene therapy addresses a diverse range of therapeutic targets, including genetic disorders, rare diseases, neurodegenerative conditions, and certain types of cancer. This diversity broadens the application of viral vectors, leading to increased production needs. The expansion of clinical trials in gene therapy and viral vaccines, driven by a robust pipeline, necessitates large-scale production of viral vectors for investigational treatments. Due to the above aspects, the market is expected to grow significantly.

Furthermore, Viral vector platforms, particularly adenoviruses, had been instrumental in developing several COVID-19 vaccines. This surge in demand had led to an increased focus on optimizing viral vector production processes to meet the global need for large-scale vaccine manufacturing. The pandemic had prompted an unprecedented acceleration of research and development efforts in the biopharmaceutical sector. This emphasis on equitable distribution had implications for the manufacturing capacity and scalability of viral vector production, driving innovations in production processes to meet the demands of a global vaccination effort. Thus, COVID-19 had a positive impact on the market.

However, Viral vector production involves complex and intricate processes, including cell culture, transfection, purification, and quality control. The complexity of these processes contributes to increased production costs, particularly in terms of skilled labor, specialized equipment, and consumables. Also, the production of viral vectors often requires specialized facilities with controlled environments to ensure the integrity and safety of the final product. Due to the above factors, market growth will be hampered in the coming years.

By Type Analysis

By type, the market is classified into adenoviral vectors, lentiviral vectors, retroviral vectors, adeno-associated viral vectors, and others. In 2022, the adeno-associated viral vectors segment registered the highest revenue share in the market. Adeno-associated viral vectors (AAVs) typically induce a minimal immune response, allowing for repeated administration without significant immune reactions. This low immunogenicity is advantageous for long-term and repeated treatments. AAVs can establish stable and long-lasting gene expression in dividing and non-dividing cells. This property is crucial for sustained therapeutic effects and reduces the need for frequent vector administration. They can infect both dividing and non-dividing partitions, making them versatile for targeting various cell types, including neurons, muscle cells, and liver cells.

By Indication Analysis

On the basis of indication, the market is segmented into cancer, genetic disorders, infectious diseases, and others. The genetic disorders segment acquired a substantial revenue share in the market in 2022. Viral vectors deliver therapeutic genes into target cells in patients with genetic disorders. The viral vector works as a delivery vehicle, carrying the corrected or functional gene to the cells affected by the genetic abnormality. This approach aims to replace or supplement the defective gene, addressing the root cause of the genetic disorder. Genetic disorders caused by enzyme deficiencies, such as lysosomal storage disorders, can be targeted using viral vectors. Introducing functional genes encoding missing enzymes into affected cells can help restore enzymatic activity and alleviate the accumulation of substrates that lead to disease symptoms.

By Application Analysis

Based on application, the market is fragmented into gene therapy and vaccinology. In 2022, the gene therapy segment held the highest revenue share in the market. Gene therapy can be applied using in vivo or ex vivo approaches. In in vivo gene therapy, viral vectors are directly administered to the patient to target specific tissues or organs. Ex vivo gene therapy involves modifying cells outside the patient's body before reinfusing them. The preference of approach depends on the target tissue and the therapeutic strategy. The increasing number of clinical trials and regulatory approvals is evidence of the success of viral vector-based gene therapies. Positive outcomes in clinical studies contribute to validating and accepting gene therapy as a viable treatment option for genetic disorders.

By Regional Analysis

Region-wise, the market is analysed across North America, Europe, Asia Pacific, and LAMEA. The Asia Pacific region covered a considerable revenue share in the market in 2022. In recent years, the Asia-Pacific region has witnessed substantial growth in the biotechnology and pharmaceutical sectors. This growth is propelled by increasing investment in research and development, expanding healthcare infrastructure, and increasing government support for the biotech industry. As a result, there is a growth in demand for viral vectors in the region to support the development and production of advanced therapies. In addition, the Asia-Pacific region has a high hindrance of cancer, genetic disorders, and infectious diseases. As a result, there is an increased focus on developing gene therapies and viral vector-based vaccines to address these healthcare challenges. The demand for viral vectors as essential tools in developing therapies drives the growth of the market.

Recent Strategies Deployed in the Market
  • Dec-2023: Oxford Biomedica plc has entered into an agreement with TSGH SAS to acquire ABL Europe SAS, a dedicated GMP CMO (Good Manufacturing Practice Contract Manufacturing Organization). Through this acquisition, Oxford Biomedica seeks to enhance its presence in the cell and gene therapy sector. Furthermore, this acquisition will not only increase Oxford Biomedica's capabilities in process and analytical development and early-stage manufacturing but also address the rising client demand for process development.
  • Oct-2023: Andelyn Biosciences, Inc. entered into partnership with Purespring Therapeutics Limited, a biotech company. Through this partnership, the companies aim to speed up the manufacturing of their gene therapies for the treatment of chronic renal diseases. Additionally, it empowers Purespring to quicken the clinical development of its gene therapy program focused on chronic kidney diseases.
  • May-2023: Oxford Biomedica plc, a Contract Development and Manufacturing Organization (CDMO) specializing in high-quality and innovative viral vectors, has launched its fourth-generation lentiviral vector delivery system, TetraVectaTM. This technology from Oxford Biomedica enhances the quality, potency, and packaging capacity of lentiviral vectors. It also integrates new and improved safety features, further enriching the company's client offerings and reinforcing its position as a leader in the LentiVector platform.
  • Mar-2023: Charles River Laboratories International, Inc. unveiled its ready-made pHelper offering. Through this product, the company aims to ensure a stable supply and simplify adeno-associated virus (AAV)-based gene therapy programs from the initial stages of discovery to commercial manufacturing. Furthermore, the product is readily accessible in Research Grade (RG), High Quality (HQ), and Good Manufacturing Practice (GMP)-grade.
  • Oct-2022: Andelyn Biosciences, Inc. has broadened its manufacturing capacities by inaugurating a new GMP clinical and commercial manufacturing facility. This facility is intended to enhance the company's ability to produce and advance cell and gene therapy (CGT). Moreover, it will facilitate viral vector production through different methods, such as adherent, iCELLis, and suspension platforms.
  • Aug-2022: Thermo Fisher Scientific, Inc. has enhanced its capabilities in cell and gene therapy by inaugurating a new viral vector manufacturing facility in Plainville, Mass. This expansion includes the support for the development, testing, and production of viral vectors—essential components in the process of developing and bringing gene therapies to market.
List of Key Companies Profiled
  • Andelyn Biosciences, Inc.
  • Charles River Laboratories International, Inc.
  • Danaher Corporation
  • FinVector Oy (Ferring Ventures S/A)
  • Thermo Fisher Scientific, Inc.
  • Novartis AG
  • Takara Bio Inc. (Takara Holdings Inc.)
  • Avid Bioservices, Inc.
  • Oxford Biomedica plc
  • Lonza Group Ltd.
Global Viral Vector Production Market Report Segmentation

By Type
  • Adeno-Associated Viral Vectors
  • Lentiviral Vectors
  • Adenoviral Vectors
  • Retroviral Vectors
  • Others
By Indication
  • Cancer
  • Genetic Disorders
  • Infectious Diseases
  • Others
By Application
  • Gene Therapy
  • Vaccinology
By Geography
  • North America
  • US
  • Canada
  • Mexico
  • Rest of North America
  • Europe
  • Germany
  • UK
  • France
  • Russia
  • Spain
  • Italy
  • Rest of Europe
  • Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Singapore
  • Malaysia
  • Rest of Asia Pacific
  • LAMEA
  • Brazil
  • Argentina
  • UAE
  • Saudi Arabia
  • South Africa
  • Nigeria
  • Rest of LAMEA


Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Global Viral Vector Production Market, by Type
1.4.2 Global Viral Vector Production Market, by Indication
1.4.3 Global Viral Vector Production Market, by Application
1.4.4 Global Viral Vector Production Market, by Geography
1.5 Methodology for the research
Chapter 2. Market at a Glance
2.1 Key Highlights
Chapter 3. Market Overview
3.1 Introduction
3.1.1 Overview
3.1.1.1 Market Composition and Scenario
3.2 Key Factors Impacting the Market
3.2.1 Market Drivers
3.2.2 Market Restraints
3.3 Porter’s Five Forces Analysis
Chapter 4. Strategies Deployed in Viral Vector Production Market
Chapter 5. Global Viral Vector Production Market, by Type
5.1 Global Adeno-Associated Viral Vectors Market, by Region
5.2 Global Lentiviral Vectors Market, by Region
5.3 Global Adenoviral Vectors Market, by Region
5.4 Global Retroviral Vectors Market, by Region
5.5 Global Others Market, by Region
Chapter 6. Global Viral Vector Production Market, by Indication
6.1 Global Cancer Market, by Region
6.2 Global Genetic Disorders Market, by Region
6.3 Global Infectious Diseases Market, by Region
6.4 Global Others Market, by Region
Chapter 7. Global Viral Vector Production Market, by Application
7.1 Global Gene Therapy Market, by Region
7.2 Global Vaccinology Market, by Region
Chapter 8. Global Viral Vector Production Market, by Region
8.1 North America Viral Vector Production Market
8.1.1 North America Viral Vector Production Market, by Type
8.1.1.1 North America Adeno-Associated Viral Vectors Market, by Country
8.1.1.2 North America Lentiviral Vectors Market, by Country
8.1.1.3 North America Adenoviral Vectors Market, by Country
8.1.1.4 North America Retroviral Vectors Market, by Country
8.1.1.5 North America Others Market, by Country
8.1.2 North America Viral Vector Production Market, by Indication
8.1.2.1 North America Cancer Market, by Country
8.1.2.2 North America Genetic Disorders Market, by Country
8.1.2.3 North America Infectious Diseases Market, by Country
8.1.2.4 North America Others Market, by Country
8.1.3 North America Viral Vector Production Market, by Application
8.1.3.1 North America Gene Therapy Market, by Country
8.1.3.2 North America Vaccinology Market, by Country
8.1.4 North America Viral Vector Production Market, by Country
8.1.4.1 US Viral Vector Production Market
8.1.4.1.1 US Viral Vector Production Market, by Type
8.1.4.1.2 US Viral Vector Production Market, by Indication
8.1.4.1.3 US Viral Vector Production Market, by Application
8.1.4.2 Canada Viral Vector Production Market
8.1.4.2.1 Canada Viral Vector Production Market, by Type
8.1.4.2.2 Canada Viral Vector Production Market, by Indication
8.1.4.2.3 Canada Viral Vector Production Market, by Application
8.1.4.3 Mexico Viral Vector Production Market
8.1.4.3.1 Mexico Viral Vector Production Market, by Type
8.1.4.3.2 Mexico Viral Vector Production Market, by Indication
8.1.4.3.3 Mexico Viral Vector Production Market, by Application
8.1.4.4 Rest of North America Viral Vector Production Market
8.1.4.4.1 Rest of North America Viral Vector Production Market, by Type
8.1.4.4.2 Rest of North America Viral Vector Production Market, by Indication
8.1.4.4.3 Rest of North America Viral Vector Production Market, by Application
8.2 Europe Viral Vector Production Market
8.2.1 Europe Viral Vector Production Market, by Type
8.2.1.1 Europe Adeno-Associated Viral Vectors Market, by Country
8.2.1.2 Europe Lentiviral Vectors Market, by Country
8.2.1.3 Europe Adenoviral Vectors Market, by Country
8.2.1.4 Europe Retroviral Vectors Market, by Country
8.2.1.5 Europe Others Market, by Country
8.2.2 Europe Viral Vector Production Market, by Indication
8.2.2.1 Europe Cancer Market, by Country
8.2.2.2 Europe Genetic Disorders Market, by Country
8.2.2.3 Europe Infectious Diseases Market, by Country
8.2.2.4 Europe Others Market, by Country
8.2.3 Europe Viral Vector Production Market, by Application
8.2.3.1 Europe Gene Therapy Market, by Country
8.2.3.2 Europe Vaccinology Market, by Country
8.2.4 Europe Viral Vector Production Market, by Country
8.2.4.1 Germany Viral Vector Production Market
8.2.4.1.1 Germany Viral Vector Production Market, by Type
8.2.4.1.2 Germany Viral Vector Production Market, by Indication
8.2.4.1.3 Germany Viral Vector Production Market, by Application
8.2.4.2 UK Viral Vector Production Market
8.2.4.2.1 UK Viral Vector Production Market, by Type
8.2.4.2.2 UK Viral Vector Production Market, by Indication
8.2.4.2.3 UK Viral Vector Production Market, by Application
8.2.4.3 France Viral Vector Production Market
8.2.4.3.1 France Viral Vector Production Market, by Type
8.2.4.3.2 France Viral Vector Production Market, by Indication
8.2.4.3.3 France Viral Vector Production Market, by Application
8.2.4.4 Russia Viral Vector Production Market
8.2.4.4.1 Russia Viral Vector Production Market, by Type
8.2.4.4.2 Russia Viral Vector Production Market, by Indication
8.2.4.4.3 Russia Viral Vector Production Market, by Application
8.2.4.5 Spain Viral Vector Production Market
8.2.4.5.1 Spain Viral Vector Production Market, by Type
8.2.4.5.2 Spain Viral Vector Production Market, by Indication
8.2.4.5.3 Spain Viral Vector Production Market, by Application
8.2.4.6 Italy Viral Vector Production Market
8.2.4.6.1 Italy Viral Vector Production Market, by Type
8.2.4.6.2 Italy Viral Vector Production Market, by Indication
8.2.4.6.3 Italy Viral Vector Production Market, by Application
8.2.4.7 Rest of Europe Viral Vector Production Market
8.2.4.7.1 Rest of Europe Viral Vector Production Market, by Type
8.2.4.7.2 Rest of Europe Viral Vector Production Market, by Indication
8.2.4.7.3 Rest of Europe Viral Vector Production Market, by Application
8.3 Asia Pacific Viral Vector Production Market
8.3.1 Asia Pacific Viral Vector Production Market, by Type
8.3.1.1 Asia Pacific Adeno-Associated Viral Vectors Market, by Country
8.3.1.2 Asia Pacific Lentiviral Vectors Market, by Country
8.3.1.3 Asia Pacific Adenoviral Vectors Market, by Country
8.3.1.4 Asia Pacific Retroviral Vectors Market, by Country
8.3.1.5 Asia Pacific Others Market, by Country
8.3.2 Asia Pacific Viral Vector Production Market, by Indication
8.3.2.1 Asia Pacific Cancer Market, by Country
8.3.2.2 Asia Pacific Genetic Disorders Market, by Country
8.3.2.3 Asia Pacific Infectious Diseases Market, by Country
8.3.2.4 Asia Pacific Others Market, by Country
8.3.3 Asia Pacific Viral Vector Production Market, by Application
8.3.3.1 Asia Pacific Gene Therapy Market, by Country
8.3.3.2 Asia Pacific Vaccinology Market, by Country
8.3.4 Asia Pacific Viral Vector Production Market, by Country
8.3.4.1 China Viral Vector Production Market
8.3.4.1.1 China Viral Vector Production Market, by Type
8.3.4.1.2 China Viral Vector Production Market, by Indication
8.3.4.1.3 China Viral Vector Production Market, by Application
8.3.4.2 Japan Viral Vector Production Market
8.3.4.2.1 Japan Viral Vector Production Market, by Type
8.3.4.2.2 Japan Viral Vector Production Market, by Indication
8.3.4.2.3 Japan Viral Vector Production Market, by Application
8.3.4.3 India Viral Vector Production Market
8.3.4.3.1 India Viral Vector Production Market, by Type
8.3.4.3.2 India Viral Vector Production Market, by Indication
8.3.4.3.3 India Viral Vector Production Market, by Application
8.3.4.4 South Korea Viral Vector Production Market
8.3.4.4.1 South Korea Viral Vector Production Market, by Type
8.3.4.4.2 South Korea Viral Vector Production Market, by Indication
8.3.4.4.3 South Korea Viral Vector Production Market, by Application
8.3.4.5 Singapore Viral Vector Production Market
8.3.4.5.1 Singapore Viral Vector Production Market, by Type
8.3.4.5.2 Singapore Viral Vector Production Market, by Indication
8.3.4.5.3 Singapore Viral Vector Production Market, by Application
8.3.4.6 Malaysia Viral Vector Production Market
8.3.4.6.1 Malaysia Viral Vector Production Market, by Type
8.3.4.6.2 Malaysia Viral Vector Production Market, by Indication
8.3.4.6.3 Malaysia Viral Vector Production Market, by Application
8.3.4.7 Rest of Asia Pacific Viral Vector Production Market
8.3.4.7.1 Rest of Asia Pacific Viral Vector Production Market, by Type
8.3.4.7.2 Rest of Asia Pacific Viral Vector Production Market, by Indication
8.3.4.7.3 Rest of Asia Pacific Viral Vector Production Market, by Application
8.4 LAMEA Viral Vector Production Market
8.4.1 LAMEA Viral Vector Production Market, by Type
8.4.1.1 LAMEA Adeno-Associated Viral Vectors Market, by Country
8.4.1.2 LAMEA Lentiviral Vectors Market, by Country
8.4.1.3 LAMEA Adenoviral Vectors Market, by Country
8.4.1.4 LAMEA Retroviral Vectors Market, by Country
8.4.1.5 LAMEA Others Market, by Country
8.4.2 LAMEA Viral Vector Production Market, by Indication
8.4.2.1 LAMEA Cancer Market, by Country
8.4.2.2 LAMEA Genetic Disorders Market, by Country
8.4.2.3 LAMEA Infectious Diseases Market, by Country
8.4.2.4 LAMEA Others Market, by Country
8.4.3 LAMEA Viral Vector Production Market, by Application
8.4.3.1 LAMEA Gene Therapy Market, by Country
8.4.3.2 LAMEA Vaccinology Market, by Country
8.4.4 LAMEA Viral Vector Production Market, by Country
8.4.4.1 Brazil Viral Vector Production Market
8.4.4.1.1 Brazil Viral Vector Production Market, by Type
8.4.4.1.2 Brazil Viral Vector Production Market, by Indication
8.4.4.1.3 Brazil Viral Vector Production Market, by Application
8.4.4.2 Argentina Viral Vector Production Market
8.4.4.2.1 Argentina Viral Vector Production Market, by Type
8.4.4.2.2 Argentina Viral Vector Production Market, by Indication
8.4.4.2.3 Argentina Viral Vector Production Market, by Application
8.4.4.3 UAE Viral Vector Production Market
8.4.4.3.1 UAE Viral Vector Production Market, by Type
8.4.4.3.2 UAE Viral Vector Production Market, by Indication
8.4.4.3.3 UAE Viral Vector Production Market, by Application
8.4.4.4 Saudi Arabia Viral Vector Production Market
8.4.4.4.1 Saudi Arabia Viral Vector Production Market, by Type
8.4.4.4.2 Saudi Arabia Viral Vector Production Market, by Indication
8.4.4.4.3 Saudi Arabia Viral Vector Production Market, by Application
8.4.4.5 South Africa Viral Vector Production Market
8.4.4.5.1 South Africa Viral Vector Production Market, by Type
8.4.4.5.2 South Africa Viral Vector Production Market, by Indication
8.4.4.5.3 South Africa Viral Vector Production Market, by Application
8.4.4.6 Nigeria Viral Vector Production Market
8.4.4.6.1 Nigeria Viral Vector Production Market, by Type
8.4.4.6.2 Nigeria Viral Vector Production Market, by Indication
8.4.4.6.3 Nigeria Viral Vector Production Market, by Application
8.4.4.7 Rest of LAMEA Viral Vector Production Market
8.4.4.7.1 Rest of LAMEA Viral Vector Production Market, by Type
8.4.4.7.2 Rest of LAMEA Viral Vector Production Market, by Indication
8.4.4.7.3 Rest of LAMEA Viral Vector Production Market, by Application
Chapter 9. Company Profiles
9.1 Andelyn Biosciences, Inc.
9.1.1 Company Overview
9.1.2 Recent strategies and developments:
9.1.2.1 Partnerships, Collaborations, and Agreements:
9.1.2.2 Geographical Expansions:
9.2 Charles River Laboratories International, Inc.
9.2.1 Company Overview
9.2.2 Financial Analysis
9.2.3 Segmental and Regional Analysis
9.2.4 Recent strategies and developments:
9.2.4.1 Product Launches and Product Expansions:
9.2.4.2 Acquisition and Mergers:
9.2.4.3 Geographical Expansions:
9.2.5 SWOT Analysis
9.3 Danaher Corporation
9.3.1 Company Overview
9.3.2 Financial Analysis
9.3.3 Segmental and Regional Analysis
9.3.4 Research & Development Expense
9.3.5 SWOT Analysis
9.4 FinVector Oy (Ferring Ventures S/A)
9.4.1 Company Overview
9.5 Thermo Fisher Scientific, Inc.
9.5.1 Company Overview
9.5.2 Financial Analysis
9.5.3 Segmental and Regional Analysis
9.5.4 Research & Development Expenses
9.5.5 Recent strategies and developments:
9.5.5.1 Acquisition and Mergers:
9.5.5.2 Geographical Expansions:
9.5.6 SWOT Analysis
9.6 Novartis AG
9.6.1 Company Overview
9.6.2 Financial Analysis
9.6.3 Segmental and Regional Analysis
9.6.4 Research & Development Expense
9.6.5 SWOT Analysis
9.7 Takara Bio Inc. (Takara Holdings Inc.)
9.7.1 Company Overview
9.7.2 Financial Analysis
9.7.3 Segmental and Regional Analysis
9.7.4 Research & Development Expenses
9.8 Avid Bioservices, Inc.
9.8.1 Company Overview
9.8.2 Financial Analysis
9.8.3 Recent strategies and developments:
9.8.3.1 Geographical Expansions:
9.9 Oxford Biomedica plc
9.9.1 Company Overview
9.9.2 Financial Analysis
9.9.3 Segmental and Regional Analysis
9.9.4 Research & Development Expenses
9.9.5 Recent strategies and developments:
9.9.5.1 Partnerships, Collaborations, and Agreements:
9.9.5.2 Product Launches and Product Expansions:
9.10. Lonza Group Ltd.
9.10.1 Company Overview
9.10.2 Financial Analysis
9.10.3 Segmental and Regional Analysis
9.10.4 Research & Development Expenses
9.10.5 SWOT Analysis
Chapter 10. Winning Imperatives of Viral Vector Production Market

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings